☰

eXmoor Pharma

Updating the operating model

Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of eXmoor Pharma's published strategy and is not endorsed by, or produced in cooperation with, eXmoor Pharma. Company website

Strategic priorities

eXmoor Pharma operates across 4 stated priorities, with the most concrete near-term plan anchored on full-service cdmo transformation.

Transitioning from 20-year consultancy heritage to end-to-end manufacturing partner offering capital consulting, process development, and GMP production under one roof.

Establishing global presence through strategic partnerships (Siam Bioscience/Bangkok) to serve Southeast Asian markets and enable decentralized manufacturing closer to patients.

Creating "joined-up translational pathways" with UCL and Royal Free London to accelerate therapies from academic research into GMP production with minimal friction.

Challenges we see

  • Digital Manufacturing

    Data Islands from Scale-Out Manufacturing

    Autologous (patient-specific) therapies require massive replication of unit operations, with each bioreactor generating independent data streams that are not centralized or easily analyzed.

    Inability to correlate process parameters across parallel production runs holds back optimization insights and extends time-to-market for client therapies.

  • Operations Integration

    Legacy Integration and Vendor Lock-in

    The Bristol facility integrates equipment from multiple vendors using proprietary protocols, resulting in "spaghetti code" for machine integration and high engineering costs for minor process changes.

    Locked into specific vendor ecosystems with astronomical custom integration fees, limiting ability to adopt best-of-breed equipment as technology evolves.

  • Compliance Operations

    Manual Data Management and Batch Release Delays

    Leadership acknowledges the industry is "not yet optimizing the handling of data," with manual data collection from disconnected devices leading to human error.

    Significantly delayed batch release process is critical for therapies with short shelf lives, directly impacting patient access and client satisfaction.

  • Compliance Regulatory

    ALCOA+ Data Integrity Compliance

    As an MHRA MIA(IMP) authorized facility, eXmoor must ensure data is Attributable, Legible, Contemporaneous, Original, and Accurate under stringent GMP standards.

    Reliance on paper-based or semi-digital systems drives audit risk and regulatory exposure, especially when proving process comparability during Phase transitions.

  • Digital Compliance

    OT/IT Cybersecurity Divergence

    Operational technology on the shop floor (bioreactors, PLCs) often lacks durable security protocols, while international partnerships (Siam Bioscience) require remote monitoring capabilities.

    High-value target for IP theft and production sabotage; remote access with international partners raises the risk of unauthorized access to client processes.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Fragmented Process Data Visibility

    Critical biological KPIs are tracked in Excel separately from live process trends, with scientists unable to customize views or correlate data across multiple bioreactors in real-time.

    Implement unified data visualization with P&ID-based dashboards that integrate offline analytical results with online sensor data, enabling real-time "Golden Batch" comparisons.

  2. Equipment Integration Complexity

    Multi-vendor equipment with proprietary protocols requires expensive custom integration, creating high engineering costs for minor process changes and limiting production flexibility.

    Deploy MTP-compliant control systems to achieve "Plug & Produce" environment, particularly for the 12,000 sq ft expansion space which can be built as a fully modular facility.

  3. Remote Collaboration and Training Gaps

    International expansion (Bangkok) and academic collaborations (UCL) create critical needs for remote oversight, standardized training, and virtual audits without expensive international travel.

    Implement AR/VR solutions for remote Factory Acceptance Tests, virtual audits of the Bangkok site, and immersive training modules for the 115 new staff members planned.

  4. Manual QC and Cell Counting Processes

    Process Development labs constantly count and classify cells manually—a monotonous task prone to human error that delays analytical workflows.

    Deploy computer vision-based automated cell counting to free technicians for complex analytical work while achieving >90% accuracy at 100+ instances per second.

  5. Predictive Process Control Gap

    Current lack of advanced predictive modeling means process deviations are identified post-facto rather than prevented, leading to batch failures and rework costs.

    Build Digital Twins of bioprocesses to execute thousands of simulations identifying optimal Critical Process Parameters before wet-lab execution, particularly valuable for complex iPSC therapies.

What we'd propose

  • Digital Lab

    Real-Time Bioprocess Intelligence Platform

    Unified data visualization and KPI automation platform transforming raw bioreactor data into actionable biological insights through P&ID-based dashboards and Golden Batch comparison.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    MTP-Compliant Modular Automation Framework

    Implementation of Module Type Package standards and OPC UA connectivity to achieve vendor-agnostic "Plug & Produce" equipment integration across the Bristol facility and expansion space.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Immersive Operations Platform (AR/VR)

    End-to-end VR/AR environment enabling remote expert collaboration, virtual facility audits, and immersive operator training to support global expansion and workforce scaling.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Computer Vision Quality Analytics

    AI-powered automated cell counting and classification system using external cameras and ML models to eliminate manual microscopy while enabling early anomaly detection.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Digital Twin Process Simulation Platform

    Cloud-agnostic simulation platform enabling virtual execution of bioprocess scenarios to optimize Critical Process Parameters and predict outcomes before wet-lab commitment.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what eXmoor Pharma's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 35 → 80
Manual Excel tracking, disconnected bioreactor data islands, no centralized analytics
Process Automation 40 → 85
Semi-automated batch records, manual cell counting, operator-dependent foam control
Equipment Connectivity 45 → 90
Multi-vendor protocols creating integration debt, no MTP adoption, limited OPC UA
Predictive Analytics 20 → 75
Post-facto deviation identification only, no digital twin capability, limited ML deployment
Remote Operations 30 → 80
Limited remote monitoring for Bangkok partnership, no AR/VR for audits or training
Cybersecurity Posture 40 → 85
OT/IT divergence acknowledged, remote access risks with international partners, IEC 62443 gap

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with eXmoor Pharma, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].